Biotech Co.* (Country; Symbol) |
Pharma Co. (Country) |
Type/Product Area |
Terms/Details (Date) |
|
| |||
| |||
airPharma* |
Britannia Pharmaceuticals Ltd. (UK) |
airPharma will develop AP0016, a dry-powder formulation of Britannia's synthetic surfactant, Pumactant |
airPharma will initiate a clinical program in respiratory indications, and assume control of the product outside the UK and Ireland; terms of the deal were not disclosed (11/9) |
| |||
Affimed Therapeutics AG* (Germany) |
Syngenta AG (Switzerland) |
Deal to co-develop an Affimed Tandab antibody for cancer and other diseases |
They will develop the molecules, which have four binding sites, under undisclosed terms (11/5) |
| |||
|
Angiotech Pharmaceuticals Inc. (Canada; ANPI) |
Boston Scientific Corp. |
Boston Scientific exercised its right to exclusively license paclitaxel and other agents in the coronary vascular field |
Angiotech's royalty increased by 1 percentage point, to between 6% and 11%; Boston Scientific also will pay $14M and a percentage of revenues for the right to sublicense the drug-eluting technology (11/23) |
| |||
|
Ansata Therapeutics Inc.* |
Medicis Pharmaceutical Corp. |
Medicis got exclusive worldwide rights to Ansata's early stage antimicrobial peptide technology |
Ansata gets $5M upon signing and about $9M in potential developmental milestone payments; additional milestones are possible; the focus is dermatology (12/14) |
| |||
Ardent Pharmaceuticals Inc.* |
ALZA Corp. |
Option and license agreement for DPI-125, Ardent's lead candidate for treating pain |
ALZA paid an initial fee for a 12-month option on exclusive rights; if exercised, Ardent would get further payments and potential milestones and royalties; it also got a co-promotion option in the U.S.; ALZA also got exclusive options to license additional analgesic compounds (11/3) |
| |||
|
Arryx Inc.* |
Haemonetics Corp. |
Collaboration to develop new technology for a range of applications |
Arryx gets a $5M equity investment and up to $12.5M in milestone payments, as well as royalties on sales; Haemonetics has exclusive rights in blood processing (10/29) |
| |||
Artemis Pharmaceuticals GmbH (Germany; subsidiary of Exelixis Inc.; EXEL) |
Schering AG (Germany) |
Artemis will generate genetically engineered mouse models for use in Schering research |
Terms of the deal were not disclosed (11/29) |
| |||
Artemis Pharmaceuticals GmbH (Germany; subsidiary of Exelixis Inc.; EXEL) |
Merck & Co. Inc. |
Artemis will construct RNAi-modified genetically engineered mice for the in vivo functional analysis of selected disease-related genes |
Terms of the deal were not disclosed (10/25) |
| |||
BioMarin Pharmaceutical Inc. (BMRN) |
Daiichi Suntory Pharma Co. Ltd. (Japan) |
Deal covering Phenoptin, an investigational oral enzyme co-factor being developed for phenylketonuria |
BioMarin gets access to data on the active ingredient of the product and would pay approval milestones and royalties outside Japan; Daiichi keeps rights in Japan (11/23) |
| |||
BioVisioN AG* (Germany) |
Novartis Pharma AG (Switzerland) |
BioVisioN will evaluate clinical samples provided by Novartis using its Differential Peptide Display technology |
The goal is to find and identify clinically relevant peptides; terms were not disclosed (12/9) |
| |||
Cambridge Antibody Technology Group plc (UK; LSE:CAT) |
AstraZeneca plc (UK) |
Deal for development of monoclonal antibody drugs that includes a five-year initial phase under which they will initiate at least 25 programs; the initial focus is inflammatory disorders |
They will share the $175M-plus cost of the discovery phase; AstraZeneca is investing $139M at a premium for a 19.9% stake in CAT; each firm has certain options to co-develop resulting products, or receive potential milestones and royalties; Astra-Zeneca also gets rights to co-develop existing CAT programs (11/22) |
| |||
Celgene Corp. (CELG) |
Various companies |
Manufacturers of isotretinoin licensed patents in order to implement a new pregnancy risk-management system |
The licenses were secured by Barr Pharmaceuticals Inc. and Mylan/Bertek, on behalf of Genpharm International Inc., Ranbaxy Laboratories Ltd. and F. Hoffmann-La Roche Ltd. (11/23) |
| |||
|
Cellomics Inc.* |
Becton, Dickinson & Co. |
BD gets access to Cellomics' High Content Screening patent portfolio |
Terms of the nonexclusive, worldwide license deal were not disclosed (11/9) |
| |||
Cell Therapeutics Inc. (CTIC) |
F. Hoffmann-La Roche Ltd. (Switzerland) |
CTI got a worldwide license to bisplatinum compounds covered by Roche patents |
Roche could earn certain milestone and royalty payments; at the same time, CTI licensed similar technology from the University of Vermont under similar terms (12/15) |
| |||
Chiron Corp. (CHIR) |
Laboratory Corp. of America Holdings |
LabCorp got a semi-exclusive license to use hepatitis C nucleic acid-testing technology in screening plasma donations in the U.S. |
As part of the deal, LabCorp agreed not to challenge the validity or enforceability of certain Chiron HCV patents; terms of the deal were not disclosed (12/3) |
| |||
Chiron Corp. (CHIR) |
F. Hoffmann-La Roche Ltd. (Switzerland) |
Roche got a nonexclusive license to develop and sell small-molecule drugs against hepatitis C virus targets |
Roche will pay up-front fees and potential milestone and royalty payments (10/26) |
| |||
Ciphergen Biosystems Inc. (CIPH) |
Pall Corp. |
They entered a collaboration on process proteomics |
The deal followed Pall's $32M acquisition of Ciphergen's BioSepra process chromatography business (11/30) |
| |||
Codexis Inc. (subsidiary of Maxygen Inc.; MAXY) |
Teva Pharmaceutical Industries Ltd. (Israel) |
Deal to develop improved processes for the manufacturing of a marketed fermented pharmaceutical product |
Codexis will use its MolecularBreeding technology in the deal, for which it will get R&D funding and potential milestone and royalty payments (12/14) |
| |||
Corixa Corp. (CRXA) |
GlaxoSmithKline plc (UK) |
GSK is acquiring worldwide rights and responsibilities associated with Bexxar sales and development |
Corixa, which made the move as part of a cost-cutting effort, will continue to get certain milestone and royalty payments; specific terms were not disclosed (12/13) |
| |||
Crucell NV (the Netherlands; CRXL) |
Edwards Lifesciences Corp. |
Edwards got rights to use the PER.C6 cell line for R&D of gene therapeutics based on adenoviral vectors |
Crucell also granted Edwards access to technical and regulatory support; terms of the nonexclusive deal were not disclosed (11/24) |
| |||
DeCode Genetics Inc. (Iceland; DCGN) |
F. Hoffmann-La Roche Ltd. (Switzerland) |
Collaboration to develop and market phosphodiesterase 4 inhibitors for preventing and treating vascular diseases |
DeCode will optimize lead compounds and begin development; the firms will share discovery and trial costs; DeCode is eligible for milestone and royalty payments (11/23) |
| |||
Dynogen Pharmaceuticals Inc.* |
Mitsubishi Pharma Corp. (Japan) |
Dynogen acquired exclusive rights to the clinical-stage compound pumosetrag |
The product (DDP733) will be developed for gastrointestinal disorders; terms of the deal were not disclosed (11/4) |
| |||
Eiffel Technologies Ltd. (Australia; ASX:EIF) |
Undisclosed company |
Deal to evaluate Eiffel's re-engineering technology with two of the partner's oral drugs |
Eiffel will apply its technology to one drug that is approved and one that is in development; terms were not disclosed (11/26) |
| |||
Eiffel Technologies Ltd. (Australia; ASX:EIF) | Undisclosed U.S. company |
Deal to develop an asthma treatment using Eiffel's re-engineered drugs and the partner's delivery device
|
Eiffel gets $0.15M up front and $0.78M in potential milestones; a license and supply deal could be signed after initial development (11/22)
|
| |||
Emisphere Technologies Inc. (EMIS) |
Novartis Pharma AG (Switzerland) |
Option and license deal on an oral form of parathyroid hormone using Emisphere's eligen delivery technology |
Emisphere received $10M in exchange for a convertible note; Emisphere is eligible for milestone payments of up to $30M, plus royalties, if Novartis exercises its option on the product (12/1) |
| |||
Emisphere Technologies Inc. (EMIS) |
F. Hoffmann-La Roche Ltd. (Switzerland) |
License deal for development of oral formulations of undisclosed compounds approved for use in the field of bone-related diseases |
Emisphere gets an initial up-front fee, and milestone payments of up to $18.5M for each product developed using its eligen technology; it also would get royalties on sales (11/18) |
| |||
Eurand International SpA* (Italy) |
Par Pharmaceutical Inc. |
Par will market Eurand's potassium chloride tablet in the U.S., where it gained approval in 3Q:04 |
Eurand gets an undisclosed up-front fee and a share of the profits (12/6) |
| |||
ExonHit Therapeutics SA* (France) |
Agilent Technologies Inc. |
Deal to develop a microarray-based solution to monitor the expression of splice variants |
They will combine Agilent's microarray platform and ExonHit's alternative RNA splicing technologies; terms were not disclosed (11/15) |
| |||
Genstruct Inc.* |
Pfizer Inc. |
Genstruct will investigate mechanism-of-action and toxicity data on Pfizer compounds |
They will work on a variety of research projects in a deal that continues an existing relationship; terms were not disclosed (11/8) |
| |||
Genzyme Corp. (GENZ) |
Wyeth |
Genzyme is repurchasing the rights to Synvisc (hylan G-F 20) in the U.S. and five European countries |
Genzyme will pay $121M in cash up front and sales milestones through June 2012 or up to $294M, whichever comes first; Genzyme also will offer jobs to 105 employees involved in U.S. Synvisc sales (11/4) |
| |||
GTx Inc. (GTXI) |
Orion Corp. (Finland) |
GTx purchased all remaining rights to toremifene in the U.S. and additional rights in all other countries |
GTx will pay $5.2M for the existing U.S Fareston business in metastatic breast cancer, and will continue developing its Acapodene product; Orion also will get royalties on Fareston sales (12/14) |
| |||
Human Genome Sciences Inc. (HGSI) |
GlaxoSmithKline plc (UK) |
GSK acquired worldwide rights to the preclinical diabetes product Albugon (albumin-GLP-1) |
HGS gets an up-front fee and clinical and commercial milestone payments that could total $183M, as well as additional milestones for other indications and royalties on any sales (10/26) |
| |||
Ingenuity Systems* |
Merck & Co. Inc. |
Merck licensed the Ingenuity Pathways Analysis application |
Merck can use the software and knowledge-base of biological networks at its sites worldwide under the multiyear deal (12/6) |
| |||
Inpharmatica Ltd.* (UK) |
Novartis Institutes for Biomedical Research |
Novartis will use Inpharmatica's Chematica technology to identify molecular targets |
Terms of the drug-discovery deal were not disclosed (12/13) |
| |||
Inpharmatica Ltd.* (UK) |
Shionogi & Co. Ltd. (Japan) |
Shionogi got a nonexclusive subscription to Biopendium Online |
Terms of the deal, involving protein annotation technology, were not disclosed (11/30) |
| |||
Integrated BioPharma Inc. (AMEX:INB) |
Fraunhofer USA Inc. |
Deal to develop a flu vaccine using transient expression vectors based on plant viruses |
The deal was made with IBP subsidiary INB Biotechnologies Inc.; terms were not disclosed (10/21) |
| |||
ISTA Pharmaceuticals Inc. (ISTA) |
Senju Pharmaceuticals Co. Ltd. (Japan) |
ISTA licensed exclusive U.S. marketing rights to ecabet sodium, an eye-drop product for treating dry-eye syndrome |
Senju gets an up-front and milestone payments, and royalties on any sales; ISTA will complete all U.S. development activities; it is the third product ISTA licensed from Senju (11/18) |
| |||
Medarex Inc. (MEDX) |
Bristol-Myers Squibb Co. |
Collaboration to develop and sell MDX-010, a fully human antibody in Phase III trials for metastatic melanoma; the deal also includes MDX-1379, a gp100 peptide that might be used with MDX-010 |
Medarex gets $25M in cash and a $25M equity investment up front, as well as up to $205M in regulatory milestones and up to $275M in sales milestones; Medarex has an option to co-promote and share profits in the U.S., and would get royalties on other sales (11/8) |
| |||
Medivir AB (Sweden; SSE: MVIR) |
Tibotec Pharmaceuticals Ltd. (Belgium; unit of Johnson & Johnson) |
Deal to discover and develop orally active inhibitors of the NS3/4A protease of the hepatitis C virus |
Medivir gets |6.5M up front, research funding and milestone payments of up to |62M; it would keep rights in Nordic countries and would receive royalties on sales elsewhere; and it could get Nordic rights to a J&J product or additional payments (11/30) |
| |||
Morphotek Inc.* |
Novo Nordisk A/S (Denmark) |
Deal to use Morphotek's Morphodoma technology to develop cell lines for manufacturing of antibodies |
Morphotek gets an up-front payment and R&D funding to support efforts to optimize up to four products; it also is eligible for licensing fees and milestone payments on the products (12/1) |
| |||
Nastech Pharmaceutical Co. Inc. (NSTK) |
Par Pharmaceutical Inc. |
Exclusive deal covering U.S. marketing of Nastech's calcitonin-salmon nasal spray for treating osteoporosis |
Nastech gets an up-front payment, regulatory and post-approval milestones, payments for final manufactured product, and a profit-sharing arrangement (10/25) |
| |||
Neurocrine Biosciences Inc. (NBIX) |
Almirall Prodesfarma SA (Spain) |
License agreement covering development of A2A receptor antagonists for Parkinson's disease |
They will share territorial rights and registration data from their respective territories for products identified during the research term; further details were not disclosed (11/10) |
| |||
Neuronova AG* (Germany) |
Prestwick Chemical Inc. (France) |
Prestwick will optimize a Neuronova small molecule with antidepressant properties |
Prestwick will apply its medicinal chemistry platform in the deal, terms of which were not disclosed (11/5) |
| |||
Norak Biosciences Inc.* |
AstraZeneca plc (UK) |
License deal allowing Astra-Zeneca to continue using Transfluor technology in its GPCR drug discovery program |
It is the second deal between the companies; terms were not disclosed (11/3) |
| |||
Novozymes A/S* (Denmark) |
Solvay Pharmaceuticals BV (Belgium) |
Collaboration to develop enzyme-replacement products for treating pancreatic exocrine insufficiency |
Solvay will pay costs related to the development of digestive enzymes; further terms were not disclosed (11/8) |
| |||
Pharmagene plc (UK; LSE:PGN) |
Bayer HealthCare AG (Germany) |
They replaced December 2003 deal under which Pharmagene provided validation services with a new services agreement |
The initial deal was for two years; Bayer now has more flexibility in using services; also, Pharmagene got rights to evaluate certain advanced preclinical compounds from Bayer now outside of Bayer's core research interests (12/13) |
| |||
Pharmasset Inc.* |
F. Hoffmann-La Roche Ltd. (Switzerland) |
Collaboration to develop nucleoside polymerase inhibitors for treating chronic hepatitis C virus infections |
Pharmasset gets an up-front fee, R&D support and milestone payments that could total $168M for the lead compound, PSI-6130; it also would get royalties, and kept certain co-promotion rights; Roche also got options to related products, and made a $4M investment in Pharmasset (10/27) |
| |||
Phytopharm plc (UK; LSE:PYM) |
Unilever plc (UK) |
Unilever got exclusive global rights to Phytopharm's Hoodia gordonii extract |
Phytopharm will get at least $12.5M and up to $40M in the deal on the obesity-targeted extract; it also would get royalties on sales (12/15) |
| |||
Plexxikon Inc.* |
Wyeth |
Deal to develop PLX204 and other small-molecule drugs targeting PPAR nuclear receptors for treating Type II diabetes and other metabolic disorders |
Plexxikon will get more than $22M in upfront and research payments, and could earn milestone payments of up to $350M; it also gets a loan to fund its share of clinical development, and would get royalties on sales (10/28) |
| |||
Procognia Ltd.* (UK) |
PerkinElmer Inc. |
Deal to distribute a solution for analysis of the glycosylation of proteins |
They will co-market the product that combines Procognia's lectin array-based platform with PE's instrumentation (12/15) |
| |||
Prometheus Laboratories Inc.* |
AstraZeneca plc (UK) |
Prometheus will exclusively market Entocort EC (budesonide) capsules in the U.S. starting Jan. 1 under a five-year deal |
The product is approved for treating mild to moderate active Crohn's disease involving the ileum and/or the ascending colon; 2004 sales were estimated at $30M; Astra-Zeneca gets an up-front payment, royalties and potential milestone payments (12/1) |
| |||
Provalis plc (UK; LSE:PRO) |
Sanofi-Aventis Group (France) |
Aventis Pasteur got an option to develop vaccine candidates to prevent Streptococcus pneumoniae infection |
Aventis will pay an initial option fee and patent-related costs; Provalis could earn milestone and royalty payments if the 24-month option is exercised (12/13) |
| |||
Purely Proteins Ltd. (UK) |
Asahi-Kasei Corp. (Japan) |
Collaboration to develop new methods for purifying proteins |
Purely Proteins will use its ligand discovery systems in the deal, terms of which were not disclosed (12/1) |
| |||
Rigel Pharmaceuticals Inc. (RIGL) |
Merck & Co. Inc. |
Collaboration to investigate ubiquitin ligases for treating cancer and other diseases; it is based on new Merck targets, and doesn't include Rigel's existing ligase targets |
Rigel gets an initial cash payment and 2.5 years of research funding; Rigel also is eligible for preclinical and clinical milestone payments, and royalties on sales; Rigel may nominate its own targets for potential inclusion in the collaboration (11/15) |
| |||
Sequella Inc.* |
Sankyo Co. Ltd. (Japan) |
Sequella licensed rights to Sankyo's anti-tuberculosis translocase inhibitors |
Sequella got all rights in all territories in exchange for potential milestone and royalty payments (11/1) |
| |||
Sequenom Inc. (SQNM) |
Siemens AG (Germany) |
To explore the requirements for next-generation molecular diagnostics platforms |
Siemens will purchase four MassArray Compact systems as part of the deal, terms of which were not disclosed (10/26) |
| |||
Triad Therapeutics Inc.* |
Novartis Pharma AG (Switzerland) |
Novartis acquired Triad's p38 kinase inhibitor program |
Triad gets an up-front payment and up to $66M in milestone payments, as well as royalties on any sales; it could earn more as new indications are developed (12/7) |
| |||
Tripos Inc. (TRPS) |
Sanofi-Aventis Group (France) |
Tripos will use its chemistry approach to design and synthesize compounds for Sanofi |
Terms of the drug discovery deal were not disclosed (11/30) |
| |||
Vaccinex Inc.* |
Biocon Ltd. (India) |
Partnership to discover and co-develop at least four therapeutic antibodies in the areas of cancer, inflammation and autoimmune disease |
The deal combines Vaccinex's antibody discovery technology with Biocon's expertise in clinical research and manufacturing; Vaccinex will receive an equity investment in the deal; further terms were not disclosed (11/18) |
| |||
Zilip-Pharma* (the Netherlands) |
Bayer HealthCare AG (Germany) |
Deal to develop a longer-acting form of Kogenate, Bayer's recombinant Factor VIII treatment for hemophilia A |
Zilip-Pharma will apply its liposome technology to Kogenate and other Factor VIII products; Bayer supported previous studies of the technology; terms were not disclosed (11/22) |
|
| |||
Notes: | |||
# The information in the chart does not cover agricultural agreements or those between biotech companies. | |||
* Private companies are indicated with an asterisk. | |||
Unless otherwise noted, stock symbols listed are on the Nasdaq market. | |||
AMEX = American Stock Exchange; ASX = Australian Stock Exchange; LSE = London Stock Exchange; SSE = Stockholm Stock Exchange. | |||
